Ads
related to: hcv polymerase inhibitors for diabetes management research- A Hep C Treatment Regimen
Ready To Treat Your Hep C?
Learn About A Treatment Option Here
- Risks Of Hepatitis C
Read About The Risks Of Hep C And
Explore A Hep C Treatment Here.
- Download A Co-Pay Coupon
Eligible Patients May Pay As Little
As $5 Per Co-Pay For A Treatment
- Patient Support Program
Looking For Financial Assistance &
Insurance Support? Learn More Here.
- Find A Hep C Provider
Ready To Take The Next Step? Find
A Hep C Provider Near You Today!
- Talk To Your Provider
Download A Conversation Guide And
Learn About A Treatment Option Here
- A Hep C Treatment Regimen
Search results
Results From The WOW.Com Content Network
The discovery of NS5A inhibitors took place within the context of a pursuit for a treatment for HCV. NS5A is among the seven nonstructural proteins that form a complex with viral RNA within infected cells to initiate HCV replication. [45] HCV research has produced several DAAs including NS3A, NS4A and NS5B inhibitors, as well as NS5A inhibitors ...
Moreover, NS5A is a key mediator in regulating host cell function and activity upon HCV infection. [4] Therefore, NS5A has been extensively studied in HCV research also due to its capability to regulate the interferon (IFN) response of the host cells. Because NS5A exerts functionally essential effects in regulation of viral replication ...
The virus is internalized and the nucleocapsid is released into the cytoplasm of the hepatocyte after binding with the receptor. The NS5B protein, which is an RNA-dependent RNA polymerase, catalyzes hepatitis C virus replication. [10] The hepatitis C virus can cause acute infection but most patients are asymptomatic upon exposure.
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; [2] it is a type of viral hepatitis. [6] During the initial infection period, people often have mild or no symptoms. [1]
Current research is focused on small-molecule inhibitors of the viral protease, RNA polymerase and other nonstructural genes. Two agents— boceprevir by Merck [ 66 ] and telaprevir by Vertex Pharmaceuticals —both inhibitors of NS3 protease were approved for use on May 13, 2011, and May 23, 2011, respectively.
The first protease inhibitor approved by the U.S. Food and Drug Administration (FDA). Ritonavir: Norvir: AbbVie: U.S. patent 5,541,206: March 1, 1996: AbbVie was part of Abbott Laboratories when patent was granted. As well as being a protease inhibitor in its own right, ritonavir inhibits the breakdown of other protease inhibitors.
Ads
related to: hcv polymerase inhibitors for diabetes management research